Related Articles
Neutrophil‑to‑lymphocyte ratio and risk of disease progression in patients with nivolumab‑treated unresectable or recurrent gastric cancer
The effect of TKI therapy and chemotherapy treatment delivery sequence on total progression‑free survival in patients with advanced EGFR‑mutated NSCLC
Efficacy of timing‑dependent infusion of nivolumab in patients with advanced gastric cancer
Safety evaluation of lenvatinib treatment after atezolizumab plus bevacizumab therapy for patients with unresectable liver cancer: A comparison of lenvatinib as 1st‑ or 2nd‑line treatment
Predictive value of inflammatory indexes on the chemotherapeutic response in patients with unresectable lung cancer: A retrospective study